A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 9, 2015, Pages 1058-1065

  Boeree, Martin J ^a   Diacon, Andreas H ^b,c   Dawson, Rodney ^d,e   Narunsky, Kim ^d,e   Du Bois, Jeannine ^c   Venter, Amour ^b   Phillips, Patrick P J ^f   Gillespie, Stephen H ^g   McHugh, Timothy D ^f   Hoelscher, Michael ^h,i   Heinrich, Norbert ^h,i   Rehal, Sunita ^f   Van Soolingen, Dick ^a,j   Van Ingen, Jakko ^a   Magis Escurra, Cecile ^a   Burger, David ^a   Van Balen, Georgette Plemper ^a   Aarnoutse, Rob E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c TASK APPLIED SCIENCE   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e Cape Town University   (South Africa)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF ST ANDREWS   (United Kingdom)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ German Center of Infection Research (DZIF) Partner Munich   (Germany)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

Antitubercular agents; Clinical trial; Dose response relationship; Drug therapy; Pharmacokinetics

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; RIFAMPICIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIMB PAIN; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; SPUTUM CULTURE; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOSE CALCULATION; DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL LOAD; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84924312172     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201407-1264OC     Document Type: Article

References (34)

1. East African and Medical Research Councils. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-1085.
2. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 2011;52: e194-199.
3. Modi M. Dose-finding studies in phase I and estimation of maximally tolerated dose. In: Ting N, editor. Dose finding in drug development. New York: Springer; 2006. p. 30-48.
4. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788.
5. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124.
6. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56:4331-4340.
7. de Steenwinkel JE, Aarnoutse RE, de Knegt GJ, ten Kate MT, Teulen M, Verbrugh HA, Boeree MJ, van Soolingen D, Bakker-Woudenberg IA. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med 2013;187:1127-1134.
8. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-949.
9. Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-1354.
10. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51: 2994-2996.
11. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011;15: 305-316.
12. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007;51:2546-2551.
13. Rifampin. Tuberculosis (Edinb) 2008;88:151-154.
14. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356:1587-1591.
15. Solera J, Rodríguez-Zapata M, Geijo P, Largo J, Paulino J, Sáez L, Martínez-Alfaro E, Sánchez L, Sepulveda MA, Ruiz-Ribó MD. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Chemother 1995; 39:2061-2067.
16. Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit SK. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 2000;93:733-737.
17. Edelstein PH, Meyer RD. Legionnaires' disease. A review. Chest 1984; 85:114-120.
18. Kissling M, Bergamini N. Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review). Chemotherapy 1981;27:368-402.
19. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-1654.
20. Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. BMJ 1971;3:343-347.
21. Boeree MJ, Diacon AH, Dawson R, Venter A, du Bois J, Narunsky K, Hoelscher M, Gillespie SH, Phillips PPJ, Aarnoutse RE. What is the "right" dose of rifampin? Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. p. 148LB.
22. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-127.
23. Sibille M, Patat A, Caplain H, Donazzolo Y. A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. Br J Clin Pharmacol 2010; 70:736-748.
24. Common terminology criteria for adverse events (CTCAE), Version 4.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009 May 28 [v4.03: 2010 Jun 14; accessed 2015 Mar 2]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf.
25. Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Maritz JS, Fourie PB. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003;1:141-155.
26. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-2835.
27. Long JS. Regression models for categorical and limited dependent variables. Thousand Oaks, CA: Sage Publications; 1997.
28. Kreis B, Pretet S, Birenbaum J, Guibout P, Hazeman JJ, Orin E, Perdrizet S, Weil J. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuberc 1976;51:71-75.
29. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013;208:1464-1473.
30. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrugresistant tuberculosis not due to noncompliance but to betweenpatient pharmacokinetic variability. J Infect Dis 2011;204: 1951-1959.
31. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012;55:169-177.
32. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012;91:881-888.
33. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27-35.
34. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005;144:80-87.